Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

CAFC
  • US 9,579,384 B2
  • Filed: 08/06/2015
  • Issued: 02/28/2017
  • Est. Priority Date: 03/20/2012
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating chronic lymphocytic leukemia or indolent B cell non-Hodgkin lymphoma in a subject comprising:

  • parenterally administering to the subject, over a period of less than or equal to about 15 minutes, a dose of from about 25 mg/m2 to about 120 mg/m2 of bendamustine or a pharmaceutically acceptable salt thereof, wherein said dose of bendamustine or pharmaceutically acceptable salt thereof is provided in a liquid composition comprising;

    a total volume of about 100 ml or less;

    bendamustine or a pharmaceutically acceptable salt thereof, at a concentration of from about 0.5 to about 5.6 mg/ml;

    a solubilizer comprising polyethylene glycol and propylene glycol, wherein the amount of solubilizer is from about 0.5 to about 26.5% by volume;

    a parenterally acceptable diluent; and

    optionally,an antioxidant.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×